ReviewFrontiers in oncology2026
De-escalating breast and axillary surgery in breast cancer: evidence, controversies, and future directions.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Surgical Burden of Breast Cancer Treatment: Implications of Mastectomy, Breast Conservation, and Reconstruction Choices.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The surgical management of breast cancer has achieved considerable improvement, shifting from radical resections toward increasingly conservative approaches driven by the advances in systemic therapy, precision imaging, and tumor biology. De-escalation strategies reducing the extent of surgery in the breast and axilla, aiming to minimize treatment-related morbidity (e.g., lymphedema, chronic pain, impaired mobility), while maintaining oncologic safety. This review synthesizes evidence from over 20 landmark trials, critically examines current clinical guidelines, and explores emerging technologies (e.g., artificial intelligence, liquid biopsy) that may further refine patient selection. We also highlight global disparities in adopting de-escalation strategies and discuss unanswered questions, such as applicability in high-risk subtypes and long-term recurrence risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.